

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

(Securities Code: 4974)

June 2, 2020

To our shareholders:

Koichi Nakao, President

Takara Bio Inc.

7-4-38, Nojihigashi, Kusatsu-shi, Shiga

Notice of the 18th Annual General Meeting of Shareholders

We are pleased to announce the 18th Annual General Meeting of Shareholders of Takara Bio Inc. (the “Company”), which will be held as indicated below.

Lately, the government and prefectural governors have been requesting people to refrain from going out in order to prevent the spread of the novel coronavirus disease (COVID-19). As a result of careful consideration in response to this situation, we have decided to hold this year’s Meeting of Shareholders upon implementing appropriate measures to prevent infection.

In view of this situation with requests of refraining from going out, from the perspective of preventing the spread of infection, we request all shareholders to exercise their voting rights in advance in writing or via the internet, etc. and to refrain from attending the meeting in person regardless of your health condition.

Please review the attached Reference Documents for General Meeting of Shareholders and exercise your voting rights by Monday, June 22, 2020, at 5:30 p.m. (JST).

[Voting via the Internet]

Please review the “Instructions on Exercise of Voting Rights via the Internet” (in Japanese only), access to the voting website designated by the Company, and enter your approval or disapproval of the proposals according to on-screen instructions by the deadline indicated above.

[Voting by Mail]

Please indicate your approval or disapproval of the proposals in the enclosed voting form and return it so that your vote is received by the voting deadline indicated above.

1. Date and Time: Tuesday, June 23, 2020, at 10:00 a.m. (JST)

2. Venue: Prince Hall, 3F, Lake Biwa Otsu Prince Hotel
4-7-7, Nionohama, Otsu-shi, Shiga

Please note that, as a measure to prevent the spread of COVID-19, shareholders will be seated at a distance from each other, and therefore there will be significantly fewer seats available compared to the past years. In light of this, please be aware that even shareholders who come to the venue may not be allowed to enter. We appreciate your understanding.

3. Purpose of the Meeting

Matters to be reported:

1. The Business Report and the Consolidated Financial Statements for the 18th fiscal year (from April 1, 2019 to March 31, 2020), and the results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit & Supervisory Board
2. The Non-consolidated Financial Statements for the 18th fiscal year (from April 1, 2019 to March 31, 2020)

Matters to be resolved:

- | | |
|-----------------------|---|
| Proposal No. 1 | Appropriation of Surplus |
| Proposal No. 2 | Election of Nine Directors |
| Proposal No. 3 | Election of Two Audit & Supervisory Board Members |

- There is concern about the spread of COVID-19. Shareholders who intend to attend this general meeting of shareholders in person are kindly requested to pay close attention to their physical condition until the day of the meeting and take care to ensure that they do not overextend themselves.
- We ask that elderly shareholders or those with underlying medical conditions, who are considered to be highly susceptible to infection, or those who are not in good health would make a careful decision to avoid the risk of infection as a matter of priority.
- At the venue of this General Meeting of Shareholders, we will take measures to prevent infection of COVID-19, such as wearing a mask and disinfecting with alcohol. We would appreciate it if you could cooperate with us in this regard.
- In order to avoid risk of infection, there will be no gifts provided at the meeting this year. We appreciate your understanding.
- We will make no area to introduce our business activities this year, which is held every year in order to gain a deeper understanding of the Company, from the viewpoint of avoiding the risk of the infection. We appreciate your understanding in advance.
- There will also be no drinks provided at the meeting this year.
- If you attend the meeting in person, please present the enclosed voting form at the venue's reception. The reception desk is scheduled to open at 9:00 a.m.
- Please note that anyone other than a shareholder who is entitled to exercise voting rights (e.g., non-shareholding proxy, person accompanying the shareholder) will not be allowed inside the venue.
- Of the documents that should be attached to the notice, the following documents are posted on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>), pursuant to laws and regulations and the provisions in Article 14 of the Company's Articles of Incorporation, and are not attached to the notice.
 1. Business Report:
Overview of Systems to Ensure Properness of Operations and Outline of Management of Such Systems
 2. Consolidated Financial Statements:
Consolidated Statement of Changes in Equity and Notes to the Consolidated Financial Statements
 3. Non-consolidated Financial Statements:
Statement of Changes in Equity and Notes to the Non-consolidated Financial Statements

Consequently, the documents attached to the notice are part of the Consolidated Financial Statements and the Non-consolidated Financial Statements that were audited by the Accounting Auditor in preparing the financial audit report and part of the Business Report, the Consolidated Financial Statements and the Non-consolidated Financial Statements that were audited by the Audit & Supervisory Board Members in preparing the audit report.
- If any revision is made to the Reference Documents for General Meeting of Shareholders, the Business Report, the Consolidated Financial Statements and the Non-consolidated Financial Statements, the Company will post such revision on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>).
- The Company participates in "electronic voting platforms" for institutional investors operated by ICJ Inc.
- To ensure that information is furnished in a timely manner, the content of this Notice was disclosed on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>) before it was sent out.

Proposal No. 2 Election of Nine Directors

At the conclusion of this meeting, the terms of office of all nine Directors will expire. In that regard, the Company proposes the election of nine Directors (three of whom are external Directors). The candidates for Director are as follows:

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
1	<p>Hisashi Omiya June 9, 1943</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company Please refer to the details below. Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1968 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>May 1974 Director</p> <p>June 1982 Managing Director</p> <p>June 1988 Senior Managing Director</p> <p>June 1991 Representative Director and Vice President</p> <p>June 1993 Representative Director and President</p> <p>Apr. 2002 Chairman of the Company (current position)</p> <p>Apr. 2002 Representative Director and President of Takara Shuzo Co., Ltd.</p> <p>June 2012 Representative Director and Chairman of Takara Holdings Inc. (current position)</p> <p> Representative Director and Chairman of Takara Shuzo Co., Ltd. (current position)</p> <p>Significant concurrent positions outside the Company</p> <p>Representative Director and Chairman of Takara Holdings Inc.</p> <p>Representative Director and Chairman of Takara Shuzo Co., Ltd.</p>	220,300 shares
<p>Reasons for nomination as candidate for Director, etc.</p> <p>Mr. Omiya is the founder of the bio business in the Takara Holdings Group and is familiar with the biotechnology industry. He possesses abundant experience and knowledge gained as an officer of the Takara Holdings Group over many years, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p>Mr. Omiya is currently a business executive (Representative Chairman and Director) of the Company's parent company Takara Holdings Inc. and its subsidiary (a so-called fellow subsidiary of the Company) Takara Shuzo Co., Ltd.</p> <p>Relationship of special interest in the Company</p> <p>The Company has the following transactions with Takara Holdings Inc. and Takara Shuzo Co., Ltd., where Mr. Omiya serves as Representative Director and Chairman.</p> <p>(i) With Takara Holdings Inc., the Company has transactions including the Company's payment of license fees for use of trademarks, payment for outsourcing of computer-related services and lease of information equipment, and transactions concerning office leases.</p> <p>(ii) With Takara Shuzo Co., Ltd., the Company has transactions including the Company's payment of office rent, payment for purchased products, and other transactions concerning product sales and contracted services.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
2	<p>Koichi Nakao June 16, 1962</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1985 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>Apr. 2002 Director of the Company</p> <p>June 2003 Managing Director and Executive Officer</p> <p>June 2004 Senior Managing Director and Executive Officer</p> <p>Apr. 2006 Senior Managing Director, Executive Officer, and COO</p> <p>June 2007 Representative Director, Vice President, Executive Officer, and COO</p> <p>June 2008 Representative Director, Vice President, and COO</p> <p>May 2009 Representative Director and President (current position)</p> <p>June 2009 Director of Takara Holdings Inc. (current position)</p> <p>June 2015 President and Executive Officer of the Company (current position)</p> <p>Significant concurrent positions outside the Company Representative Director and President of Takara Bio USA Holdings Inc. Director of Takara Holdings Inc.</p>	68,600 shares
<p>Reasons for nomination as candidate for Director, etc.</p> <p>Mr. Nakao has displayed leadership as Representative Director of the Company and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p>Mr. Nakao is currently a business executive (Representative Director and President) of Takara Bio USA Holdings Inc., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company. Within the past five years, Mr. Nakao has served as a business executive (Chairman) of Takara Biotechnology (Dalian) Co., Ltd., Takara Biomedical Technology (Beijing) Co., Ltd., and Takara Korea Biomedical Inc., which are subsidiaries of the Company's parent company Takara Holdings Inc. as well as subsidiaries of the Company.</p>			
3	<p>Shuichiro Matsuzaki September 5, 1955</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1980 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>June 2005 Director</p> <p>June 2007 Director</p> <p>June 2008 Director of Takara Shuzo Co., Ltd. Director of Takara Holdings Inc. Managing Director of Takara Shuzo Co., Ltd.</p> <p>June 2010 Director of Takara Holdings Inc. Senior Managing Director of Takara Shuzo Co., Ltd.</p> <p>June 2014 Senior Managing Director of the Company</p> <p>June 2015 Senior Managing Director and Senior Managing Executive Officer</p> <p>June 2017 Director, Vice President and Executive Vice President</p> <p>June 2019 Representative Director, Vice President and Executive Vice President (current position)</p> <p>Current responsibility in the Company CFO (Chief Financial Officer)</p>	12,300 shares
<p>Reasons for nomination as candidate for Director</p> <p>Mr. Matsuzaki possesses abundant experience and knowledge gained in Business Management, IR, Finance and Accounting as an officer of Takara Holdings Inc. and Takara Shuzo Co., Ltd., and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
4	<p>Junichi Mineno August 13, 1960</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1984 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>Apr. 2004 General Manager of Center for Cell and Gene Therapy Facility of the Company</p> <p>June 2009 Deputy General Manager of Gene Therapy Business Unit and General Manager of Center for Cell and Gene Therapy Facility</p> <p>Apr. 2011 Executive Officer</p> <p>June 2012 Senior Executive Officer</p> <p>June 2014 Managing Director</p> <p>June 2015 Managing Director and Senior Executive Officer</p> <p>June 2019 Director and Senior Managing Executive Officer (current position)</p> <p>Current responsibility in the Company COO (Chief Operating Officer)</p> <p>Significant concurrent positions outside the Company Representative Director and Vice Chairman of Takara Korea Biomedical Inc.</p>	14,400 shares
<p>Reasons for nomination as candidate for Director, etc.</p> <p>Mr. Mineno has engaged in R&D of new technologies and new projects, genetic analysis-related business and businesses related to products and services for clinical research on cell and gene therapies. He possesses a track record of establishing its GMP production framework in the gene therapy business, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p>Mr. Mineno is currently a business executive (Representative Director and Vice Chairman) of Takara Korea Biomedical Inc., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company.</p>			
5	<p>Masanobu Kimura August 19, 1963</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>July 2001 Joined Daiichi Pharmaceutical Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)</p> <p>Mar. 2007 Joined ImmunoFrontier, Inc.</p> <p>Mar. 2010 Joined ICON Japan K.K.</p> <p>Nov. 2011 Joined PAREXEL International Inc.</p> <p>May 2013 Joined the Company</p> <p>Apr. 2015 Deputy General Manager of Gene Therapy Business Unit and General Manager of Project Management Department</p> <p>June 2016 Executive Officer</p> <p>June 2017 Director and Managing Executive Officer (current position)</p> <p>Current responsibility in the Company General Manager of Clinical Development Division</p>	800 shares
<p>Reasons for nomination as candidate for Director</p> <p>Mr. Kimura has been involved in development of pharmaceuticals, has leadership experience in clinical development in the gene therapy business, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
6	<p>Tsuyoshi Miyamura October 20, 1963</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1988 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>Jan. 2009 General Manager of Sales Department of the Company</p> <p>June 2009 Executive Officer</p> <p>June 2014 Managing Executive Officer (current position)</p> <p>June 2018 Director (current position)</p> <p>Current responsibility in the Company General Manager of Sales & Marketing Division</p> <p>Significant concurrent positions outside the Company Chairman of Takara Biomedical Technology (Beijing) Co., Ltd.</p>	8,900 shares
<p>Reasons for nomination as candidate for Director, etc.</p> <p>Mr. Miyamura has been involved in planning, marketing, sales and distribution of products and services in the bio business, has contributed to the market expansion in China for products in the genetic engineering research field, proved his ability as a corporate manager for the Company's subsidiary, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as Director.</p> <p>Mr. Miyamura is currently a business executive (Chairman) of Takara Biomedical Technology (Beijing) Co., Ltd., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company.</p> <p>Within the past five years, Mr. Miyamura has served as a business executive (Chairman) of Takara Biotechnology (Dalian) Co., Ltd., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
	<p>Nobuko Kawashima October 27, 1962 (Name as shown on the family register: Nobuko Yokoyama)</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p> <p>Number of years in office as an external Director 4 years (at the conclusion of this meeting)</p>	<p>Apr. 1986 Joined The Long-Term Credit Bank of Japan, Limited</p> <p>Sept. 1987 Joined Dentsu Communication Institute Inc.</p> <p>Sept. 1995 Research fellow at the Centre for Cultural Policy Studies of the University of Warwick</p> <p>Apr. 1999 Full-time lecturer with the Faculty of Economics at Doshisha University</p> <p>Apr. 2004 Professor with the Faculty of Economics (current position)</p> <p>June 2016 Director (external Director) of the Company (current position)</p> <p>Significant concurrent positions outside the Company Professor with the Faculty of Economics at Doshisha University</p>	<p>0 shares</p>
7	<p>Reasons for nomination as candidate for external Director, etc.</p> <ul style="list-style-type: none"> - Ms. Kawashima is a candidate for external Director. - Ms. Kawashima has extensive research experience in subjects including creative economy and corporate social responsibility. She meets the criteria for candidates for external Director established by the Company, and is expected to apply her expert knowledge to the management of the Company and express her opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated her as a candidate to continue serving as an external Director. - Ms. Kawashima has never in the past been involved in the management of a company except as an external officer. However, the Company judges she will appropriately fulfill her duties as an external Director based on her abundant experience as an academic and broad insight on economy and society. - Ms. Kawashima satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning her appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Ms. Kawashima to limit her liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Ms. Kawashima is approved, the Company plans to renew the aforementioned agreements with her.</p>		

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
8	<p style="text-align: center;">Kazuko Kimura May 1, 1951 [Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 10/10 (100%)</p> <p>Number of years in office as an external Director 1 years (at the conclusion of this meeting)</p>	<p>Apr. 1976 Safety and Environmental Health Bureau, Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare)</p> <p>Apr. 1979 Pharmaceutical Affairs Bureau</p> <p>July 1996 Pharmaceutical Department of World Health Organization (on secondment)</p> <p>July 1999 Organization for Pharmaceutical Safety and Research (on secondment)</p> <p>Apr. 2000 Professor of International Medical Research Laboratory, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University</p> <p>June 2013 Director (Outside Director) of Alfresa Holdings Corporation</p> <p>Sept. 2013 Representative Director of Medicines Security Workshop (current position)</p> <p>Apr. 2017 Professor Emeritus of National University Corporation Kanazawa University (current position)</p> <p>Oct. 2017 Specially Appointed Professor of Graduate School of Medical Sciences (current position)</p> <p>June 2019 Director (external Director) of the Company (current position)</p> <p>Significant concurrent positions outside the Company Specially Appointed Professor of Graduate School of Medical Sciences, National University Corporation Kanazawa University Representative Director of Medicines Security Workshop</p>	0 shares
<p>Reasons for nomination as candidate for external Director, etc.</p> <ul style="list-style-type: none"> - Ms. Kimura is a candidate for external Director. - Ms. Kimura is a specialist in the areas of quality control of pharmaceutical distribution, eradication of substandard and falsified medicines, support of development of anti-counterfeit technologies, and education of specialists. She meets the criteria for candidates for external Director established by the Company, and is expected to apply her expert knowledge to the management of the Company and express her opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated her as a candidate to continue serving as an external Director. - Ms. Kimura has never in the past been involved in the management of a company except as an external officer. However, the Company judges she will appropriately fulfill her duties as an external Director based on her abundant experience as an academic and broad insight on quality control of pharmaceutical distribution, etc. - Ms. Kimura satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning her appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Ms. Kimura to limit her liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Ms. Kimura is approved, the Company plans to renew the aforementioned agreements with her.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
9	<p>Noriomi Matsumura July 10, 1971</p> <p>[New election - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings -</p>	<p>May 1998 Medical Staff with Department of Obstetrics and Gynecology at Hyogo Prefectural Amagasaki Hospital</p> <p>Apr. 2000 Medical Staff with Department of Obstetrics and Gynecology at Toyooka Public Hospital</p> <p>Sept. 2002 Medical Staff with Department of Obstetrics and Gynecology at Kyoto University Hospital</p> <p>Apr. 2007 Clinical Assistant Professor with Department of Obstetrics and Gynecology at National University Corporation Kyoto University Hospital</p> <p>Apr. 2008 Assistant Professor with Department of Gynecology and Obstetric</p> <p>Dec. 2012 Lecturer with Maternal and Perinatal Care Unit</p> <p>Aug. 2013 Associate Professor with Department of Gynecology and Obstetrics</p> <p>Apr. 2017 Professor with Department of Obstetrics and Gynecology of Faculty of Medicine at Kindai University (current position)</p> <p>June 2017 Vice Chairperson of Board Certification Committee of Japan Society of Obstetrics and Gynecology (current position)</p> <p>Dec. 2018 Director and TR Committee Member, Japanese Gynecologic Oncology Group (current position)</p> <p>Significant concurrent positions outside the Company Professor with Department of Obstetrics and Gynecology of Faculty of Medicine at Kindai University</p>	0 shares
<p>Reasons for nomination as candidate for external Director, etc.</p> <ul style="list-style-type: none"> - Mr. Matsumura is a candidate for external Director. - Mr. Matsumura possesses abundant experience and expert knowledge in obstetrics and gynecology and other fields of medical science in general, and is familiar particularly with the areas of tumor genome analysis, molecular targeted therapy, and immune therapy of gynecologic oncology. He meets the criteria for candidates for external Director established by the Company, and is expected to utilize his experience and expertise and express his opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated him as a candidate for external Director. - Mr. Matsumura has never in the past been involved in the management of a company except as an external officer. However, the Company judges he will appropriately fulfill his duties as an external Director based on his abundant experience as an academic and broad insight on medical science in general. - Mr. Matsumura satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company plans to submit notification to the aforementioned exchange concerning his appointment as an independent officer. <p>Limited liability agreement</p> <p>If the election of Mr. Matsumura is approved, pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company plans to enter into an agreement with him to limit his liability for damages stipulated in Article 423, paragraph 1 of the same Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act.</p>			

Proposal No. 3 Election of Two Audit & Supervisory Board Members

The term of office of Audit & Supervisory Board Members Kunihiko Kamada and Yasuo Himejiwa will expire at the conclusion of this meeting.

Therefore, the Company proposes the election of two Audit & Supervisory Board Members (two external Audit & Supervisory Board Members).

In addition, the consent of the Audit & Supervisory Board has been obtained for this proposal.

The candidates for Audit & Supervisory Board Member are as follows:

Candidate No.	Name (Date of birth)	Career summary and position in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
1	<p>Kunihiko Kamada May 16, 1960</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p> <p>Attendance at Audit & Supervisory Board meetings 13/13 (100%)</p> <p>Number of years in office as an Audit & Supervisory Board Member 4 years (at the conclusion of this meeting)</p>	<p>Apr. 1992 Registered as an attorney at law (Osaka Bar Association)</p> <p>Mar. 1993 Registered as a patent attorney</p> <p>Apr. 2007 Part-time lecturer at Meijo University (current position)</p> <p>Jan. 2011 Partner of Daiichi Legal Professional Corporation (current position)</p> <p>June 2016 Audit & Supervisory Board Member (External Audit & Supervisory Board Member) of the Company (current position)</p> <p>Significant concurrent positions outside the Company Partner of Daiichi Legal Professional Corporation</p>	0 shares
<p>Reasons for nomination as candidate for external Audit & Supervisory Board Member, etc.</p> <ul style="list-style-type: none"> - Mr. Kamada is a candidate for external Audit & Supervisory Board Member. - Mr. Kamada meets the criteria for candidates for external Audit & Supervisory Board Member established by the Company, and is expected to provide advice and recommendations to promote compliance management and to ensure the validity and appropriateness of decisions made by the Board of Directors and the Audit & Supervisory Board by utilizing his advanced expert knowledge and experience as an attorney at law. Therefore, the Company nominated him as a candidate to continue serving as an external Audit & Supervisory Board Member. - Mr. Kamada has never in the past been involved in the management of a company except as an external officer. However, the Company judges that he will appropriately fulfill his duties as an external Audit & Supervisory Board Member based on the above reasons. - Mr. Kamada satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning his appointment as an independent officer. <p>Limited liability agreement Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Mr. Kamada to limit his liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Mr. Kamada is approved, the Company plans to renew the aforementioned agreements with him.</p>			

Candidate No.	Name (Date of birth)	Career summary and position in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
2	<p>Yasuo Himeiwa November 5, 1953</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p> <p>Attendance at Audit & Supervisory Board meetings 13/13 (100%)</p> <p>Number of years in office as an Audit & Supervisory Board Member 4 years (at the conclusion of this meeting)</p>	<p>Aug. 1983 Joined the accounting firm of Peat Marwick Mitchell & Co. (currently KPMG)</p> <p>Aug. 1990 Registered as a certified public accountant of Japan</p> <p>Aug. 1992 Assigned to KPMG London Office</p> <p>Aug. 1994 European Director of KPMG Project Japan</p> <p>Jan. 1996 Partner of Century Audit Corporation (currently Ernst & Young ShinNihon LLC)</p> <p>Feb. 2001 Senior Partner of Shin Nihon & Co. (currently Ernst & Young ShinNihon LLC)</p> <p>Sept. 2003 Partner of AZSA & Co.</p> <p>July 2009 Head of Global Japanese Practice Osaka Office</p> <p>May 2015 Chairman of National Employee Association of KPMG AZSA LLC</p> <p>June 2016 Director of Himeiwa CPA Office (current position) Audit & Supervisory Board Member (External Audit & Supervisory Board Member) of the Company (current position)</p> <p>June 2017 Outside Director (Audit and Supervisory Committee Member) of Sharp Corporation (current position)</p> <p>June 2020 Outside Director (Audit and Supervisory Committee Member) of IDEC CORPORATION (scheduled to assume the position)</p> <p>Significant concurrent positions outside the Company Director of Himeiwa CPA Office Outside Director (Audit and Supervisory Committee Member) of Sharp Corporation Outside Director (Audit and Supervisory Committee Member) of IDEC CORPORATION [scheduled to assume the position on June, 2020]</p>	0 shares
<p>Reasons for nomination as candidate for external Audit & Supervisory Board Member, etc.</p> <ul style="list-style-type: none"> - Mr. Himeiwa is a candidate for external Audit & Supervisory Board Member. - Mr. Himeiwa meets the criteria for candidates for external Audit & Supervisory Board Member established by the Company, and is expected to provide advice and recommendations to improve transparency and objectivity in management by utilizing his advanced expert knowledge and experience in finance and accounting as a certified public accountant. Therefore, the Company nominated him as a candidate to continue serving as an external Audit & Supervisory Board Member. - Mr. Himeiwa satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning his appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Mr. Himeiwa to limit his liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Mr. Himeiwa is approved, the Company plans to renew the aforementioned agreements with him.</p>			